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Background: The primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS)
versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The
secondary aims were to compare pathological effects, short-term mortality and morbidity, and to evaluate the effect of lymph
node harvest upon survival in both treatment groups.
Methods: Data were collected from 10 European centers from 2001 to 2012. Six hundred and eight patients with stage II or III
oesophageal or oesophago-gastric junctional adenocarcinoma were included; 301 in the NCRS group and 307 in the NCS group.
Propensity score matching and Cox regression analyses were used to compensate for differences in baseline characteristics.
Results: NCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%; P< 0.001), more ypN0 (63.3%
versus 32.1%; P< 0.001), and reduced R1/2 resection margins (7.7% versus 21.8%; P< 0.001). Analysis of short-term outcomes
showed no statistically significant differences in 30-day or 90-day mortality, but increased incidence of anastomotic leak (23.1%
versus 6.8%; P< 0.001) in NCRS patients.
There were no statistically significant differences between the groups in 3-year overall survival (57.9% versus 53.4%; Hazard Ratio
(HR)¼ 0.89, 95%C.I. 0.67-1.17, P¼ 0.391) nor disease-free survival (52.9% versus 48.9%; HR¼ 0.90, 95%C.I. 0.69-1.18, P¼ 0.443). The
pattern of recurrence was also similar (P¼ 0.660). There was a higher lymph node harvest in the NCS group (27 versus 14;
P< 0.001), which was significantly associated with a lower recurrence rate and improved disease free survival within the NCS
group.
Conclusion: The survival differences between NCRS and NCS maybe modest, if present at all, for the treatment of locally
advanced esophageal or junctional adenocarcinoma. Future large-scale randomized trials must control and monitor indicators
of the quality of surgery, as the extent of lymphadenectomy appears to influence prognosis in patients treated with NCS, from
this large multi-center European study.
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Introduction
Multimodality treatment of esophageal cancer is the standard of
care in Western centers, although surgery remains the primary
curative modality. Two neoadjuvant approaches have been
adopted. The first is neoadjuvant chemoradiotherapy, based in
recent years on the CROSS regimen which resulted in a 5-year
survival advantage of 14% in comparison with surgery alone
[1, 2]. An alternative option is perioperative or preoperative
chemotherapy using the MAGIC or OEO2 protocol, which
showed, respectively, 5-year survival improvements of 13% and
6% compared with surgery alone [3, 4]. The maximum benefit in
the CROSS-trial was observed in squamous cell carcinoma, with
highly significant (HR¼ 0.48; 95%C.I. 0.28–0.83; P¼ 0.009)
benefit compared with surgery alone, in comparison with adeno-
carcinoma, where the benefit was more modest (HR¼ 0.73;
95%C.I.0.55–0.98; P¼ 0.037), but the benefit of neoadjuvant
chemoradiotherapy was consistent across subgroups, without
any significant interaction identified [1, 2]. Moreover, two small
underpowered randomized trials comprising 119 and 75 patients
with esophageal adenocarcinoma did not show a significant dif-
ference in survival between neoadjuvant chemoradiotherapy plus
surgery versus neoadjuvant chemotherapy plus surgery [5, 6].
The recently reported NeoRES trial in a mixed cohort of 181 pa-
tients with esophageal adenocarcinoma and squamous cell car-
cinoma, showed pathological benefits without any changes in
survival associated with the addition of radiotherapy to neoadju-
vant chemotherapy [7].
Therefore, the optimal multimodality treatment for esophageal
adenocarcinoma remains undetermined and is the subject of in-
vestigation in the more recently initiated Neo-AEGIS trial, which
randomizes patients (n¼ 574) with adenocarcinoma of the
esophagus or esophago-gastric junction to the CROSS or
MAGIC regimens, and is likely to be reported in 2021 [8].
The primary aim of the present retrospective multicenter
European study was to compare survival from neoadjuvant che-
moradiotherapy plus surgery (NCRS) versus neoadjuvant
chemotherapy plus surgery (NCS) for the treatment of adenocar-
cinoma of the esophagus or esophago-gastric junction. The sec-
ondary aims were to compare pathological effects, short-term
mortality and morbidity and to evaluate the effect of lymph node
harvest upon survival in both treatment groups. The current
retrospective study described herein was aimed to reach a sample
size similar to the ongoing Neo-AEGIS trial [8].
Methods
Datasets
Consecutive patient data were retrieved from 10 prospectively maintained
surgical European single-center databases; (i) Erasmus MC—University
Medical Centre, Rotterdam, Netherlands; (ii) Academic Medical Centre,
Amsterdam, Netherlands; (iii) VU Medical Centre, Amsterdam,
Netherlands; (iv) Catharina Hospital, Eindhoven, Netherlands; (v)
University Medical Centre, Groningen, Netherlands; (vi) Radboud
University Nijmegen Medical Centre, Nijmegen, Netherlands; (vii)
Rijnstate Hospital, Arnhem, Netherlands; (viii) St James’s Hospital,
Dublin, Ireland; (ix) Imperial College London, UK; and (x) Oxford
University Hospitals, Oxford, UK. The datasets have been externally
validated and are maintained as part of their respective countries national
cancer audits. All patients with adenocarcinoma of the NCRS-arm within
the CROSS-trial were included [1, 2]. Management plans and allocation of
neoadjuvant therapy were decided upon at multi-disciplinary tumor
boards at all centers participating in this study. The study period was from
2001 to 2012 with patient follow-up until December 2015.
Inclusion criteria
The study included patients with stage II or III esophageal or esophago-
gastric junctional (Siewert type I and II) adenocarcinoma treated with
neoadjuvant chemoradiotherapy plus surgery (CROSS regimen; NCRS
group) [1, 2] or peri-/preoperative chemotherapy plus surgery (mainly
MAGIC, OEO2 or OEO5 regimens; NCS group) (supplementary
Appendix A, available at Annals of Oncology online) [3, 4, 9].
Exclusion criteria
The study did not include (i) patients with esophageal squamous cell car-
cinoma; (ii) patients with Siewert type III adenocarcinoma; and (iii) pa-
tients treated with definitive chemoradiotherapy. Furthermore, patients
who underwent exploratory surgery but did not undergo surgical resec-
tion of the tumor due to tumor progression were excluded, as data were
not routinely collected as part of the datasets included.
Clinical staging and follow-up
The approach to clinical pretreatment staging used a combination of
endoscopic ultrasound (EUS), computerized tomography (CT) and on
demand CT-positron emission tomography (CT-PET). EUS was used in
98.3% of patients in the NCRS group and 90.2% of patients in the NCS
group. In all centers, after surgery patients were reviewed every 3 months
during the first year. In the second year, follow-up took place every 6
months, and annually thereafter until 5 years. In cases of suspected recur-
rence, thoraco-abdominal CT, PET-CT, and/or upper gastrointestinal
endoscopy were performed. Histological, cytological, or unequivocal
radiological proof was required before a diagnosis of recurrence was
made. The first site of recurrence was used to define whether loco-
regional, distant, or mixed relapse had occurred. Median follow-up was
33.5 months (range 0.03–177.8 months), with 46 patients having follow-
up of less than 3 years during the study period; 29 (15.8%) in the NCS
group and 17 (11.8%) in the NCRS group.
Outcomes
The primary outcome measure was 3-year overall survival. Secondary
outcomes included: 3-year disease-free survival; pattern of recurrence
(within 3-years); pathological T-stage and N-stage (TNM7) [10]; tumor
regression grade (TRG) as reported by Chirieac et al. [11]; 30-day and 90-
day mortality; and 30-day morbidity, specifically anastomotic and chyle
leak, pulmonary and cardiac complications, and reoperation. The time
for overall survival was defined from date of surgery to date of death or
date of last follow-up. The time for disease-free survival was defined from
date of surgery and the earliest occurrence of disease progression result-
ing from loco-regional recurrence or distant dissemination, or death
from any cause [1, 12].
Statistical analysis
Data are presented as prevalence (percentage), median (range), and for
survival as median (95% confidence interval). Continuous variables are
expressed as mean6 standard deviation or median (range) and categor-
ical variables as percentage. A Mann–Whitney test was used for inter-
group comparisons of continuous variables, whereas a v2 test or Fisher’s
exact test was used to compare categorical data. Overall and disease-free
survivals were estimated using the Kaplan–Meier method. The log rank
test was used to compare survival curves. Missing data were at random
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and, therefore, only available data were analyzed, in multivariate regres-
sion analysis listwise deletion was used.
Propensity matching
In order to reduce the effects of potential confounding factors in the
comparisons of short and mid-term outcomes between groups, a pro-
pensity score (PS) was calculated to create well-balanced groups. The PS
was estimated using a multivariable logistic regression model, with the
treatment groups as the dependent variables and potential confounders
as covariates. The following confounders were included in the propensity
matching: age70 years; male gender; American Society of
Anesthesiologists (ASA) grade; clinical tumour (cT) stage; and clinical
nodal (cN) positivity or negativity. All patients in the NCS group were
matched 1:1 to patients in the NCRS group according to the propensity
score using the global optimum method [13].
Cox regression analysis
Year of surgery and age as continuous variables were not included in the
PS matching, as this would have further reduced the dataset dramatically
to maintain a good level of matching (fewer than 10 patients per group,
and neither demonstrated multivariate associations with endpoints).
Therefore, overall- and disease-free survivals were also compared be-
tween groups using a multivariable Cox regression model. In this model,
adjustment was performed for the same characteristics as in the PS ap-
proach, with the addition of year of surgery and age as continuous
variable.
Risk-adjusted cumulative sum (RA-CUSUM) curve
analysis for the effect of lymph node harvest on
survival
RA-CUSUM analysis was used to determine a lymph node harvest
threshold that affected overall survival in each of NCRS and NCS groups
[14]. The threshold was defined as the minimum lymph node harvest for
an alteration in overall survival relationships. Risk prediction models for
overall survival were created using regression models. Potential risk fac-
tors included in the models were: age, male gender, ASA grade, and clin-
ical T and N stages. The risk prediction models were used to calculate the
predicted probability of survival in each case. For the CUSUM curve, the
sum of all events was compared with the expected sum of events accord-
ing to the risk-adjustment model, using the CUSUM equation Si¼Si-
1þ (Ri- RR); S0¼0: Si is the cumulative sum, R i the sum of events at pro-
cedure number i, and RR the sum of expected events at procedure num-
ber i. The clinical impact of the threshold was determined by comparing
the survival and recurrence rates before and after the change-point in
overall survival. To ascertain whether the change-points observed in the
CUSUM curves were reliable, we bootstrapped each curve with 1000 iter-
ations to identify the confidence level (CL) of the change point. We com-
puted the CUSUM values at the change point (n¼ 1000). We
hypothesized that a reliable change point would have a CUSUM value
that was greater than at least 95% of the simulated CUSUM values
(CL> 95%).
CUSUM curves were computed using Excel (Excel for Mac 2011, ver-
sion 14.1.4, Microsoft Corporation, Redmond, WA, USA). For the re-
maining statistical analysis, SPSS software was used (Statistical Package
for the Social Sciences software, Version 22, SPSS, Chicago, IL, USA).
Results
Over the 12-year study period 608 patients were included: 301 in
the NCRS group and 307 in the NCS group. The NCRS group con-
sisted of patients from the centers, which participated in the
CROSS-trial [1, 2] and St James’s Hospital, Dublin, whereas NCS
patients were provided by Imperial College in London, Oxford
University Hospitals in Oxford and St James’s Hospital in Dublin.
During the study period, no patients with oesophageal adenocar-
cinoma from Imperial College London or Oxford University hos-
pital received neoadjuvant chemoradiotherapy. Within the Dutch
cohort, during the study period, less than 3% of patients could not
undergo radiotherapy (e.g. due to history of radiotherapy) or had
lymph nodes outside the maximum radiation field, received neo-
adjuvant chemotherapy, and were excluded from the study. From
the NCS group, the number of patients receiving MAGIC/ECF re-
gime was 51 (16.6%), OEO2/CF 138 (45%), OEO5/ECX was 87
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Figure 1. (A) Unmatched Kaplan–Meier survival analysis showing a
signiﬁcant (P¼ 0.047) improvement in overall survival with neoadju-
vant chemoradiotherapy plus surgery (NCRS, n¼ 301) compared
with neoadjuvant chemotherapy plus surgery (NCS, n¼ 307) for
esophageal adenocarcinoma. (B) Propensity-matched Kaplan–Meier
survival analysis showing no signiﬁcant difference (P¼ 0.391) in over-
all survival between neoadjuvant chemoradiotherapy plus surgery
(NCRS, n¼ 221) and neoadjuvant chemotherapy plus surgery (NCS,
n¼ 221) for esophageal adenocarcinoma.
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(28.3%), EOX 21 (6.8%), and other regimes 10 (3.3%). After pro-
pensity matching, 442 patients were included in the analysis; 221
in the NCRS group and 221 in the NCS group.
Comparison of patient demographics and
treatment strategies (Table 1)
Analysis of patient demographics before matching, showed a signifi-
cantly lower median age and greater numbers of patients with ASA I
in NCRS versus NCS group. After propensity matching, there were
no significant differences between the groups in age, patients aged
70 years or older, distribution of patients by ASA grade, WHO per-
formance status and clinical T and N stages. After matching, there
were significantly more transhiatal resections (61.5% versus 0.5%;
P< 0.001) and significantly fewer transthoracic resections (36.7%
versus 94.6%; P< 0.001) for NCRS versus NCS.
Comparison of tumor pathology and short-term
outcomes (Tables 2 and 3)
Both before and after matching, utilization of chemoradiotherapy
was associated with significantly more down-staging. This is re-
flected in the matched comparison by significantly increased inci-
dence of ypT0 (26.7% versus 5%; P< 0.001), ypN0 (63.3% versus
32.1%; P< 0.001) in the NCRS group compared with the NCS
group. Neoadjuvant chemoradiotherapy was also associated with a
significant reduction in the incidence of R1/2 resection margins
(7.7% versus 21.8%; P< 0.001). The NCRS group had a signifi-
cantly lower median number of harvested lymph nodes (14 versus
27; P< 0.001) and positive lymph nodes (0 versus 2; P< 0.001) in
comparison with the NCS group. After matching, analysis of short-
term outcomes showed no significant differences in 30-day mortal-
ity (4.1% versus 1.4%, P¼ 0.140) or 90-day mortality (5.9% versus
2.3%) and morbidity apart from an increased incidence of anasto-
motic leak (23.1% versus 6.8%; P< 0.001) in the NCRS group.
Comparison of survival and recurrence, propensity
matched (Table 3 and Figure 1)
Unmatched survival analysis suggested that NCRS was associated
with a small improvement in 3-year overall survival (57.8% ver-
sus 49.8%; HR 0.79, 95%C.I. 0.63–1.00; P¼ 0.052) (Figure 1A:
log rank test P¼ 0.047). There was no significant difference in 3-
year disease-free survival between unmatched groups (52.8% ver-
sus 46.9%; HR 0.85; 95%C.I. 0.68–1.07; P¼ 0.163). After match-
ing, observed differences between the groups in 3-year overall
(57.9% versus 53.4%; HR 0.89, 95%C.I. 0.67–1.17, P¼ 0.391)
Table 1. Comparative analysis of patient demographics and surgical techniques from unmatched and propensity-matched groups
Before matching After matching
NCRS (n5301) (%) NCS (n5307) (%) P value NCRS (n5221) (%) NCS (n5221) (%) P value
Age (median (range)) 61.3 (19–83) 63.9 (30–82) 0.013 62 (19–83) 63.3 (30–82) 0.936
Age  70 66 (21.9) 88 (28.7) 0.056 50 (22.6) 50 (22.6) >0.999
Male 258 (85.7) 252 (82.1) 0.224 192 (86.9) 192 (86.9) >0.999
ASA a
I 54 (19.4) 18 (5.9) <0.001 16 (7.2) 16 (7.2) >0.999
II 190 (68.1) 214 (69.7) 173 (78.3) 173 (78.3)
III 35 (12.5) 74 (24.1) 32 (14.5) 32 (14.5)
IV 0 (0) 1 (0.3) 0 (0) 0 (0)
WHO performance status a
0 252 (83.7) 113 (89) 0.293 181 (81.9) 61 (88.4) 0.381
1 47 (15.6) 14 (11) 38 (17.2) 8 (11.6)
2 2 (0.7) 0 (0) 2 (0.9) 0 (0)
cT stagea
1 10 (3.4) 6 (2) 0.120 3 (1.4) 3 (1.4) >0.999
2 43 (14.4) 36 (11.7) 23 (10.4) 23 (10.4)
3 236 (79.2) 248 (80.8) 187 (84.6) 187 (84.6)
4 9 (3) 17 (5.5) 8 (3.6) 8 (3.6)
cN stage a
Negative 108 (35.9) 93 (30.3) 0.17 69 (31.2) 69 (31.2) >0.999
Positive 193 (64.1) 214 (69.7) 152 (68.8) 152 (68.8)
Operation
Transhiatal 168 (55.8) 1 (0.3) <0.0001 136 (61.5) 1 (0.5) <0.001
Transthoracic 127 (42.2) 284 (92.5) 81 (36.7) 209 (94.6)
3-Stage 6 (2) 22 (7.2) 4 (1.8) 11 (5)
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant chemotherapy and surgery; ASA, American Society of Anesthesiologists
classiﬁcation.
aMissing data.
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Table 2. Comparative analysis of tumor pathology from unmatched and propensity-matched groups
Before matching After matching
NCRS (n5 301) (%) NCS (n5307) (%) P value NCRS (n5221) (%) NCS (n5221) (%) P value
Tumour location a
Proximal 1 (0.3) 0 (0) 0.141 1 (0.5) 0 (0) 0.329
Middle 13 (4.4) 6 (2) 9 (4.1) 5 (2.3)
Distal/EGJ 284 (95.3) 300 (98) 210 (95.5) 216 (97.7)
pT stage a
0 85 (28.2) 16 (5.2) <0.001 59 (26.7) 11 (5) <0.001
I 45 (15) 27 (8.8) 32 (14.5) 19 (8.6)
2 61 (20.3) 76 (24.8) 49 (22.2) 58 (26.2)
3 108 (35.9) 174 (56.9) 79 (35.7) 125 (56.6)
4 2 (0.7) 13 (4.2) 2 (0.9) 8 (3.6)
pN stage
0 189 (62.8) 98 (31.9) <0.001 140 (63.3) 71 (32.1) <0.001
1 82 (27.2) 92 (30) 65 (29.4) 76 (34.4)
2 21 (7) 57 (18.6) 11 (5) 41 (18.6)
3 9 (3) 60 (19.5) 5 (2.3) 33 (14.9)
Mandard TRG a
1 85 (28.5) 14 (5.4) <0.001 59 (27.1) 11 (5.6) <0.001
2 73 (24.5) 19 (7.4) 58 (26.6) 12 (6.1)
3 80 (26.8) 46 (17.8) 62 (28.4) 32 (16.3)
4/5 60 (20.1) 178 (68.9) 39 (17.9) 141 (71.9)
Resection margin a
R0 278 (92.4) 220 (77.5) <0.001 204 (92.3) 165 (78.2) <0.001
R1/2 23 (7.6) 64 (22.5) 17 (7.7) 46 (21.8)
LN harvest (median
(range)) 15 (0–53) 31 (0–129) <0.001 14 (0–52) 27 (0–129) <0.001
Total 0 (0–28) 2 (0–44) <0.001 0 (0–9) 2 (0–33) <0.001
Positive
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant chemotherapy and surgery; EGJ, oesophago-gastric junction; TRG, tumour regres-
sion grade.
aMissing data.
Table 3. Comparative analysis of short-term outcomes and three-year recurrence from unmatched and propensity-matched groups.
Before matching After matching
NCRS (n5301) (%) NCS (n5307) (%) P value NCRS (n5221) (%) NCS (n5221) (%) P value
30-day mortality 9 (3) 5 (1.6) 0.263 9 (4.1) 3 (1.4) 0.140
90-day mortality 15 (5) 7 (2.3) 0.074 13 (5.9) 5 (2.3) 0.090
Anastomotic leak a 61 (20.4) 15 (5.6) <0.001 51 (23.1) 13 (6.8) <0.001
Pulmonary complications a 135 (44.9) 103 (38.9) 0.15 101 (45.7) 72 (38.3) 0.134
Cardiac complications a 58 (19.3) 56 (21.1) 0.581 43 (19.5) 36 (19.1) >0.999
Chyle leak a 22 (7.3) 24 (9.1) 0.448 17 (7.7) 13 (6.9) 0.850
Reoperation 27 (9.1) 20 (6.5) 0.108 22 (10.2) 14 (6.5) 0.050
Recurrence
Locoregional 15 (5.0) 19 (6.2) 0.542 10 (4.5) 14 (6.3) 0.660
Distant 73 (24.3) 70 (22.8) 56 (25.3) 60 (27.1)
Mixed 30 (10.0) 22 (7.2) 19 (8.6) 14 (6.3)
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant chemotherapy and surgery.
aMissing data.
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(Figure 1B) or disease-free survival (52.9% versus 48.9%; HR
0.90, 95%C.I. 0.69–1.18, P¼ 0.443) were small and statistically
non-significant. Following matching, there were no significant
differences between the groups in the pattern of recurrence
(P¼ 0.660) (Table 3).
Comparison of survival and recurrence, Cox
regression (Table 4)
Cox regression analysis including year of treatment and age, as
continuous variables did not show significant differences between
NCRS and NCS in 3-year overall (HR 0.86; 95%C.I. 0.66–1.11;
P¼ 0.232) and 3-year disease-free survival (HR 0.91; 95%C.I.
0.71–1.16; P¼ 0.459) (Table 4).
RA-CUSUM analysis of lymph node harvest
(Figure 2)
In the NCRS group, RA-CUSUM analysis showed that lymph
node harvest did not affect survival or recurrence with no identi-
fiable change-point in the RA-CUSUM curve (Figure 2A).
In the NCS group, lymph node harvest significantly influenced
survival and recurrence. The mean change-point in overall sur-
vival was seen to lie between 22 and 52 lymph nodes (confidence
level 95.4%) (Figure 2B). At a lymph node harvest threshold of 52
lymph nodes, there were significant improvements in disease-free
survival (22–36 months; P¼ 0.028), and overall recurrence
(47.1%–15.9%; P< 0.001). However, the improvement in overall
survival remained non-significant (27–38 months; P¼ 0.171).
Discussion
The present study showed no significant differences in overall or
disease-free 3-year survival or pattern of recurrence between
NCRS and NCS groups after propensity matching and Cox re-
gression analysis. This is despite neoadjuvant chemoradiotherapy
conferring significant pathological benefits in terms of tumor and
nodal down staging and tumor regression grade. Lymph node
harvest uniquely in the NCS group was shown to be significantly
associated with disease-free survival and recurrence with an opti-
mal threshold between 22 and 52 lymph nodes removed.
Although the incidence of anastomotic leak was higher in the
NCRS group, in-hospital mortality and other major postopera-
tive complications were similar.
This study is the largest available analysis that compares NCRS
with NCS for the treatment of esophageal and junctional adeno-
carcinoma. Despite higher rates of ypT0, ypN0, and R0 in the
NCRS group, only small non-significant survival differences in
overall and disease-free 3-year survival were evident. This might
be partially explained by a non-significant increase in postopera-
tive mortality rate in the NCRS group. This apparent paradox of
significant down-staging at primary and nodal sites, yet no sur-
vival benefit, was also evident in three small underpowered
randomized trials [5–7]. Taken together, these results suggest
that survival differences between NCRS and NCS may be rela-
tively modest, if present at all, and suggest that a large sample size
is required for prospective RCTs that compare these modalities.
One intriguing element of the analysis is that the extent of lym-
phadenectomy may have impacted on disease-free survival and
cancer recurrence exclusively in the NCS group. The absence of
an association between lymph node harvest and survival in the
NCRS group is consistent with the analysis of patients from the
CROSS trial and further non-randomized data, which found that
the total number of resected nodes was associated with survival in
the surgery-alone group but not in the NCRS group [15, 16].
These results suggest that regional control of esophageal adeno-
carcinoma is essential and might either be achieved through
chemotherapy with radical lymphadenectomy or neoadjuvant
chemoradiotherapy with limited lymphadenectomy.
It was not possible to match for surgical technique as only one
patient had transhiatal resection in the NCS group. At the centers
where both transhiatal and transthoracic esophagectomies were
performed, no significant difference in survival between the two
techniques has been reported [17]. The difference in technique
may be responsible for the observed differences in lymph node
harvest between the NCRS and NCS groups, in line with results
from randomized controlled trials [17–19]. Moreover, in the
CROSS-trial lymph node, retrieval after neoadjuvant chemora-
diotherapy appeared to be lower than after surgery alone (14 ver-
sus 18 lymph nodes, respectively), even when using the same
surgical technique [15]. Other authors have also reported that
chemoradiotherapy reduces lymph node harvest from within the
radiotherapy field, e.g. in rectal cancer [20, 21]. The median
number of lymph nodes retrieved in the NCRS group was 14.
Consequently, in the present study, it was not possible to examine
the added value of radical lymphadenectomy to neoadjuvant che-
moradiotherapy on survival for esophageal adenocarcinoma, and
this aspect will be of great interest in future trials such as Neo-
AEGIS. The analysis in our study indicates that the quality of
Table 4. Cox regression analysis for overall survival, with correction for
year of treatment and age as continuous variables
Hazard ratio 95% Confidence interval
Lower Upper P value
Neoadjuvant therapy
NCS 1.00 0.66 1.11 0.232
NCRS 0.86
Age 1.01 1.00 1.02 0.195
Gender
Male 1.00 0.62 1.21 0.402
Female 0.87
ASA 0.013
I 1.00 0.70 1.56 0.839
II 1.04 1.01 2.53 0.045
III and IV 1.60
cT stage 0.038
1 1.00 0.21 1.05 0.065
2 0.47 0.39 1.64 0.541
3 and 4 0.80
cN stage
cN0 1.00 1.17 2.05 0.002
cNpositive 1.55
Year of surgery 0.98 0.93 1.02 0.306
NCRS, neoadjuvant chemoradiotherapy and surgery; NCS, neoadjuvant
chemotherapy and surgery.
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surgery, using lymph node retrieval as a proxy for quality and ex-
tent of lymphadenectomy, remains an important prognostic fac-
tor affecting the outcome from multimodality treatment of
esophageal adenocarcinoma. We have previously shown that as-
surance of surgical quality within randomized controlled trials
for the treatment of esophago-gastric cancer is an important as-
pect of study design and can affect variation in lymph node har-
vest and mortality [22]. Nevertheless, a recent analysis of the
MAGIC trial has also shown that the presence of lymph node
metastases after chemotherapy is an independent predictor of
overall survival, although authors did not include lymph node
count in the multivariate analysis [23].
Analysis of short-term outcomes showed no significant differ-
ence between NCRS and NCS apart from an increased incidence of
anastomotic leak in the NCRS group. There was a non-significant
increase in 30-day (4.1% versus 1.4%; P¼ 0.140) and 90-day mor-
tality (5.9% versus 2.3%; P¼ 0.090) in the NCRS group. The
centers involved in this study were high volume units, with all pro-
cedures performed by high volume surgeons, thus minimizing the
effect of surgeon and hospital volume on short-term outcomes
[24–26]. A significantly higher proportion of patients in the NCRS
group had transhiatal resection with cervical esophageal anasto-
mosis, which is known to be associated with a higher leak rate than
thoracic anastomosis [27]. Theoretically, radiotherapy might affect
perfusion of the gastric tube and thus anastomotic healing; this
notwithstanding, no differences in anastomotic leak were found
between the NCRS and surgery alone groups of the CROSS-trial.
This effect is currently being further explored in an ongoing Dutch
randomized trial comparing cervical with thoracic anastomosis
after neoadjuvant chemoradiation [28].
There are limitations that must be considered in interpreting
the results of this analysis, foremost its design as a retrospective,
observational study. The propensity-matched analysis controlled
for important factors that can influence long-term survival and
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Figure 2. (A) RA-CUSUM analysis of lymph node harvest versus overall survival in chemoradiotherapy plus surgery group (NCRS); lymph
node harvest does not affect survival with no discernable pattern to this CUSUM curve. (B) RA-CUSUM analysis of lymph node harvest versus
overall survival in chemotherapy plus surgery group (NCS); change point as illustrated by the plateau of curve at 22–52 lymph nodes. Above
52 lymph nodes there were signiﬁcant improvements in disease-free survival (22–36 months; P¼ 0.028), and overall recurrence (47.1%–
15.9%; P< 0.001) and non-signiﬁcant improvement in overall survival (27–38 months; P¼ 0.171).
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cancer recurrence. However, both ASA-classification and cN sta-
tus are subjective parameters in their clinical application that
might have influenced the matching process. There may have
been a small degree of selection bias within the Dutch cohort dur-
ing the study period as less than 3% of patients could not undergo
radiotherapy (e.g. due to history of radiotherapy) or had sus-
pected lymph nodes outside the maximum radiation field, there-
fore, underwent neoadjuvant chemotherapy, and were excluded
from the study. However, after matching 84.6% and 68.8% of pa-
tients in both groups had cT3 and cN positive staging, respect-
ively, which is representative of the esophageal cancer population
in Europe. Nevertheless, it was not possible to examine the bene-
fits of NCS and NCRS separately for early and advanced disease
because of the sample size of matched patients. Furthermore,
there are inevitably other confounding variables including het-
erogeneity in surgical approach and type of chemotherapy used
in the NCS group that may have varied between the groups.
Moreover, the propensity matching reduced the sample size, re-
sulting in less statistical power compared with the recently initi-
ated Neo-AEGIS trial, and especially impeded correction for year
of treatment and age as continuous variables. To overcome this
limitation, data were also analyzed using Cox regression analysis.
During the study period, there was some variation in the defin-
ition of complications, with the international consensus only re-
cently published [29]. However, anastomotic leak was defined
similarly in all centers with clinical or radiological evidence of
leak and postoperative contrast evaluation of the anastomosis
was standard of care in all participating centers. Unfortunately,
data on toxicity of chemoradiotherapy and chemotherapy were
not available in all participating centers. Patients were selected
based on whether they underwent surgical resection (and not on
whether they were planned to undergo NCS or NCRS), which
impeded an intention-to-treat analysis. Therefore, patients not
surgically resected due to disease progression, complete clinical
response or patient physiological status were not included in this
study. In the CROSS trial, 10% of patients in the multimodality
arm did not undergo surgical resection due to toxicity or tumour
progression, whereas in the MAGIC trial and OEO2 trial this was
17% and 14%, respectively [3, 4]. Finally, follow-up was not suffi-
cient to compare long-term (5-year) survival between NCRS
[2] and NCS, further emphasizing the need for publication of the
long-term results from the MAGIC-trial.
In conclusion, this multi-center European study suggests that
any prognostic differences between neoadjuvant chemoradio-
therapy plus surgery and neoadjuvant chemotherapy plus surgery
for the treatment of locally advanced esophageal and junctional
adenocarcinoma are likely to be small. Our study suggests that
loco-regional tumor control is of great importance, and can
either be achieved through neoadjuvant chemotherapy with ex-
tended lymphadenectomy or concurrent chemoradiotherapy
with limited lymphadenectomy. The benefit, if any, of extended
lymphadenectomy after neoadjuvant chemoradiotherapy has not
been addressed by this study and remains unclear. Therefore, fu-
ture randomized trials evaluating multimodality treatment of
esophageal adenocarcinoma must not only comprise an adequate
sample size, but must also control and monitor quality of surgery
during the trial. We would like to emphasize that this retrospect-
ive study does not provide a definitive answer to the unsolved
question of the comparative benefits on NCS and NCRS in
esophageal adenocarcinoma but supports the importance of the
ongoing NeoAEGIS trial and its surgical quality measures.
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